⌘K

07:00:00·61d

PRReleasevia Quantisnow

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

ByQuantisnow·Wall Street's wire, on your screen.

PHAT· Phathom Pharmaceuticals Inc.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

PHAT
Phathom Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Mar 27UpdateBarclays$18.00
Dec 12UpdateRaymond James$28.00
Dec 9UpdateBarclays$16.00
Feb 14UpdateCantor Fitzgerald$23.00
May 3UpdateStifel$24.00
Jan 5UpdateNeedham$26.00

Related

PR8d
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
SEC21d
SEC Form DEFA14A filed by Phathom Pharmaceuticals Inc.
SEC21d
SEC Form DEF 14A filed by Phathom Pharmaceuticals Inc.
PR22d
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
SEC32d
SEC Form S-8 filed by Phathom Pharmaceuticals Inc.
ANALYST32d
Phathom Pharmaceuticals upgraded by Barclays with a new price target
SEC47d
SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.
INSIDER48d
SEC Form 4 filed by Phathom Pharmaceuticals Inc.